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Rapamycin has emerged as a potential therapeutic drug for mitochondrial diseases since it has shown therapeu-
tic benefits in a fewmouse models of mitochondrial disorders. However, the underlying therapeutic mechanism
is unclear, the minimal effective dose needs to be defined and whether this therapy can be generally used is un-
known.
Methods:Wehave evaluatedwhether low and high doses of rapamycin administrationmay result in therapeutic
effects in amouse model (Coq9R239X) of mitochondrial encephalopathy due to CoQ deficiency. The evaluation in-
volved phenotypic, molecular, image (histopathology and MRI), metabolomics, transcriptomics and bioenerget-
ics analyses.
Findings: Low dose of rapamycin induces metabolic changes in liver and transcriptomics modifications in mid-
brain. The high dose of rapamycin induces further changes in the transcriptomics profile in midbrain due to
the general inhibition of mTORC1. However, neither low nor high dose of rapamycin were able to improve the
mitochondrial bioenergetics, the brain injuries and the phenotypic characteristics of Coq9R239X mice, resulting
in the lack of efficacy for increasing the survival.
Interpretation: These results may be due to the lack of microgliosis-derived neuroinflammation, the limitation to
induce autophagy, or the need of a functional CoQ-junction. Therefore, the translation of rapamycin therapy into
the clinic for patients with mitochondrial disorders requires, at least, the consideration of the particularities of
each mitochondrial disease.
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Mouse model1. Introduction
Mitochondrial disorders comprise the most common group of in-
born errors of metabolism and the therapeutic options for most of
these diseases are limited to palliative care. However, a promising
drug-based therapy was reported in 2013 in a mouse model of mito-
chondrial disease due to mitochondrial complex I deficiency [1]. In
that study, Johnson and colleagues demonstrated that chronic adminis-
tration of a high dose of rapamycin, a compound that inhibits a proteingía, Centro de Investigación
ocimiento s/n, 18016, Granada,
.V. This is an open access article undkinase calledmechanistic target of rapamycin complex 1 (mTORC1), de-
lays the onset and progression of neurological symptoms in a mouse
model of Leigh syndrome and mitochondrial complex I deficiency due
to the lack of the Ndufs4 subunit of the mitochondrial complex I [1].
mTORC1 lies at the hub of cellular signaling sensing nutrient availability
to regulate protein and lipid synthesis, translation, autophagy, and me-
tabolism. However, the mechanism by which rapamycin delayed the
progression of the disease in the Ndufs4−/− mouse model was not
clear since the evaluated pathways did not provide convincing results
and themutantmice still presented a severe mitochondrial dysfunction
[1]. Moreover, the study of Johnson and colleagues [1] left opened two
important questions about the therapeutic feasibility of rapamycin ther-
apy in mitochondrial diseases: (1) whether rapamycin would be effec-
tive in a human equivalent dose (the equivalent dose used by Johnsoner the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Research in context
Evidence before this study
Rapamycin therapy has shown therapeutic benefits in a few
mouse models of mitochondrial diseases, opening the possibility
of the translation of this therapeutic option into the clinic. How-
ever, a common therapeutic mechanism has not been identified
and it is unclear whether rapamycin would be effective in a
human equivalent dose or whether mTORC1 inhibition would be
useful only in specific cases of mitochondrial dysfunction or in all
cases of mitochondrial diseases.
Added value of this study
This study reports that rapamycin administration, at either low or
high doses, does not result in therapeutic benefits in a mouse
model of mitochondrial encephalopathy due to CoQ deficiency.
The molecular, transcriptomics and metabolic analyses provide
important insights about the dose-dependent and tissue-specific
effects of rapamycin in vivo.
Implications of all the available evidence
These results are important for the translational perspective of
rapamycin therapy, since it points out the limitation of this thera-
peutic strategy for some particular cases of mitochondrial dis-
eases. The identification of specific mechanistic changes may
contribute to the future definition of rapamycin therapy in patients
with mitochondrial diseases.
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to avoid side effects), which has been used, among others, in animal
studies about aging [2]; and (2) whether mTORC1 inhibition would be
useful only in cases ofNdufs4deficiency, in cases of complex I deficiency,
in all cases of Leigh syndrome or mitochondrial encephalopathies or in
all cases of mitochondrial diseases.
Other mitochondrial disorder different from Complex I deficiency is
Coenzyme Q10 (CoQ10) deficiency syndrome (OMIM 607426), which is
clinically manifested by five major phenotypes: encephalomyopathy,
severe infantile multisystemic disease, nephropathy, cerebellar ataxia,
and isolated myopathy [3]. The encephalomyopatic phenotype associ-
ated to CoQ deficiency has been mimicked in the Coq9R239X mouse
model, which has a reduction in the components of the Complex
Q with the subsequent decrease in the levels of CoQ and accumulation
of demethoxyubiquinone (DMQ); disruption in sulfide metabolism; in-
crease in free complex III in the brain, leading to a decrease inmitochon-
drial respiration and ATP synthesis, as well as to an increase of oxidative
stress; and severe reactive astrogliosis and spongiform degen-
eration with early death. Therefore, Coq9R239X mice show clinical,
histopathological, biochemical and molecular signs of encephalopathy,
representing an excellent model to test therapies for mitochondrial dis-
eases [4].
In this study, we evaluated whether low and high doses of rapa-
mycin administration may result in therapeutic effects in a mouse
model of mitochondrial encephalomyopathy due to CoQ deficiency.
For that purpose, we studied the main pathways related to mTORC1
and mitochondrial metabolism and performed a more general tran-
scriptomics and metabolomics profile. Moreover, we made a pilot
study to test two drugs, trehalose [5] and PF-4708671 [6], thatmodulate
autophagy or lipid synthesis and protein translation, respectively, two
of the downstream pathways of mTORC1.2. Material and methods
2.1. Mouse model and treatments
The Coq9R239X mouse model of mitochondrial encephalomyopathy
used in this study was generated and characterized under mix of
C57BL/6N and C57BL/6J genetic backgrounds as reported previously
[4,7]. Coq9R239X/+ mice were crossbred in order to generate Coq9+/+,
Coq9R239X/+, Coq9R239X/R239X (referred in the article as Coq9R239X). Only
homozygouswild-type andmutantmicewere used in the study. All ex-
periments were performed according to a protocol approved by the In-
stitutional Animal Care and Use Committee of the University of Granada
(procedure CEEA 2014-64) and were in accordance with the European
Convention for the Protection of Vertebrate Animals used for Experi-
mental and Other Scientific Purposes (CETS # 123) and the Spanish
law (R.D. 53/2013). Mice were housed in the Animal Facility of the Uni-
versity of Granada under a specific pathogen free zone with lights on
at 7:00 AM and off at 7:00 PM with unlimited access to water and ro-
dent chow.
Rapamycin (from LC Labs, Woburn, MA) was microencapsulated by
Southwest Research Institute (San Antonio, TX), using a spinning disk
atomization coating process with the enteric coating material Eudragit
S100 (Röhm Pharma, Germany) [2]. Standard mouse chow was ground
to a powder and mixed with microencapsulated rapamycin at 28 or
225 ppm. 300 ml of 1% agar melted in sterile water was added per kilo-
gram of powdered chow and the mixture was pelleted and baked at
55 °C for 2–3 h to harden. Pellets were stored at 4 °C (short-term stor-
age) or −20 °C (long-term storage). Control food contained no drug
but microencapsulation material (Eudragit S100) alone at a concentra-
tion matching that in the rapamycin chow, as indicated.
Trehalose was given to themice in their drinkingwater at a concen-
tration of 2% (w/v) [5]. PF-4708671 treatment was administered by
daily intraperitoneal injection at a concentration of 35 mg/kg/d [8].
The drug was dissolved at 5 mg/ml in 40% PEG400, 27.5% PG, 0.25%
Tween80 in PBS. This vehicle without PF-4708671 was also injected in
Coq9R239X mice as a control.
Mice began receiving the assigned treatments at 1month of age and
were euthanized at 3 months of age for the experimental assays. Ani-
mals were randomly assigned in experimental groups. Data were ran-
domly collected and processed as well.
The body weight was collected throughout the treatment, before
starting (0 months) and at 1 and 2 months after the treatment (what
corresponds with 1, 2 and 3 months of age). The motor coordination
was assessed using the rotarod test by recording length of time that
mice could remain on the rod (“latency to fall”) up to 300 s [9].
2.2. Sample preparation and western blot analysis in tissues
Western blot analyses were performed in cerebrum, kidney, heart
and liver as previously described [7]. Band quantification was carried
out using an Image Station 2000R (Kodak, Spain) and a Kodak 1D 3.6
software. Protein band intensity was normalized to GAPDH, and the
data expressed in terms of percent relative to wild-type mice.
The following primary antibodieswere used: anti-phospho-S6 Ribo-
somal Protein (Ser235/236) (Cell Signaling, 4856S), anti-S6 Ribosomal
Protein (Cell Signaling, 2217S), anti-SQSTM1/p62 (Proteintech, 18420-
1-AP), anti-LC3 (Novusbio, NB100–2220), and anti-GAPDH (Santa
Cruz Biotechnology, sc-166574).
2.3. Quantification of CoQ9 and CoQ10 levels in mice tissues
After lipid extraction from homogenized tissues, CoQ9 and CoQ10
levels were determined via reversed-phase HPLC coupled to electro-
chemical (EC) detection [4,7]. The results were expressed in ng
CoQ/mg prot.
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activities
Mitochondrial isolation was performed as previously described
[10]. After tissues homogenization, brain and kidney homogenates
were centrifuged at 1000 ×g for 5 min at 4 °C to remove nuclei and
debris. Mitochondria were collected from supernatants after
centrifuging at 14,400 ×g for 2 min at 4 °C (twice). The final crude
mitochondrial pellet was store at −80 °C [11].
CoQ dependent respiratory chain activities were measured in
submitochondrial particles. To prepare submitochondrial particles,
each mitochondrial pellet (100 μg prots) was suspended and soni-
cated in 100 μl of 0.1 M potassium phosphate buffer, pH 7.5. Complex
I + III activity was measured at 30 °C in the presence of 0.5 mM po-
tassium cyanide, 0.2 mM NADH and 0.1 mM cytochrome c, as the
rotenone-sensitive reduction of cytochrome c at 550 nm [11]. The re-
sults were expressed in percentage relative to the wild type. Com-
plex II + III activity was measured at 30 °C in the presence of
0.5 mM KCN, 0.3 mM succinate and 0.01 mM rotenone. The reaction
was initiated by addition of 0.1 mM cytochrome c and decrease in
absorbance was monitored at 550 nm. The results were expressed
in percentage relative to the wild type.
2.5. Mitochondrial respiration
To isolate fresh mitochondria, mice were sacrificed and the organs
were immediately extracted and placed in ice. The final crude mito-
chondrial pellet was re-suspended in MAS 1×medium [7,9]. Mitochon-
drial respiration was measured by using an XFe24 Extracellular Flux
Analyzer (Seahorse Bioscience) [12]. Respiration by the mitochondria
was sequentially measured in a coupled state with the substrates (suc-
cinate, malate, glutamate, and pyruvate) present (basal respiration or
State 2), followed by State 3o (phosphorylating respiration, in the pres-
ence of ADP and substrates); State 4 (non-phosphorylating or resting
respiration) was measured after addition of oligomycin when all ADP
was consumed, and then maximal uncoupler-stimulated respiration
(State 3u) [7,9]. All data were expressed in pmol/min/mg protein.
2.6. Histology and immunohistochemistry
Mice brains were formalin fixed and paraffin embedded. Multiple
sections (4 μm thickness) were deparaffinized with xylene and stained
with hematoxylin and eosin (H&E). Immunohistochemistrywas carried
out in the same sections, using the following primary antibodies: Glial
fibrillary acidic protein or anti-GFAP (Millipore, MAB360), and anti-
Iba-1 (Wako, 019-19741). Dako Animal Research Kit for mouse primary
antibodies (Dako Diagnóstico S.A., Spain) was used for the qualitative
identification of antigens by light microscopy. Sections were examined
at 40–400 magnifications with an OLYMPUS CX41 microscope, and
the images were scanned under equal light conditions with the CELL A
computer program [4]. The GFAP positive signal was quantified by
using the software ImageJ (National Institutes of Health, USA) and the
results were expressed by the percentage of the positive signal.
2.7. In vivo MRI and proton MRS
MRI and MRS studies were conducted using a 7T horizontal bore
magnet Bruker Biospec TM 70/20 USR designed for small animal exper-
imentation, as previously reported [9,13].
2.8. Transcriptome analysis by RNA-seq
For the RNA-Seq we dissected themidbrain of the animals. RNAwas
extracted following the TRI Reagent Solution protocol from Applied
Biosystems. Library preparation and sequencing was performed at the
Transcriptome and Genome Analysis Laboratory, NGS Core Unit at theUniversitzy Medical Center Göttingen. Quality and integrity of RNA
was assessed with the Fragment Analyzer from Advanced Analytical
by using the standard sensitivity RNA Analysis Kit (DNF-471). All sam-
ples selected for sequencing exhibited an RNA integrity number over
8. RNA-seq libraries were performed using 500 ng total RNA of a non
stranded RNA Seq, massively-parallel mRNA sequencing approach
from Illumina (TruSeq RNA Library Preparation Kit v2, Set A; 48 sam-
ples, 12 indexes, Cat. NRS-122-2001).
For accurate quantitation of cDNA libraries a fluorometric based sys-
tem, the QuantiFluor™dsDNA System from Promega were used. The
size of final cDNA libraries was determined by using the dsDNA 905 Re-
agent Kit (FragmentAnalyzer fromAdvanced Bioanalytical) exhibiting a
sizing of 300 bp in average. Libraries were pooled and sequenced on the
Illumina HiSeq 4000 (SE; 1 × 50 bp; 30–35 Mio reads/sample).
Sequence images were transformed with Illumina software Base-
Caller to BCL files, whichwas demultiplexed to fastq files with bcl2fastq
v2.17.1.14. The quality check was done using FastQC (version 0.11.5,
Babraham Bioinformatics). Sequenced reads (Illumina 50 bp single-
end)weremapped to the reference genome using the TopHat2 (version
2.1.0) and the quantification of transcripts was performed with
Cufflinks (version 2.2.1), using Partek Flow (Partek, St. Louis, MO,
USA). The data were RMA normalized. The list of differentially
expressed genes (DEG) was obtained by ANOVA filtering with FDR
correcting with a cut-off of adjusted P-value b 0.05. The fold changes
are represented as log2FC (base-2 logarithm of the fold change) [14].
2.9. Rapamycin levels in blood
Whole-blood samples were collected during the light cycle in EDTA
tubes by puncture in the facial vein of animals at 3 months of age. 50 μl
of each samplewasmixedwith 75 μl of 0.1M ZnSO4 and 125 μl of meth-
anol during 30 min. After centrifugation at 14,000 rpm during 10 min,
the supernatants were collected and injected into a liquid chromatogra-
phy system H-Class (WatersCorporation) coupled to a Xevo TQS detec-
tor of mass spectrometer (MS/MS) with an electrospray ionization
(Waters Corporation). The analytical separation column was a BEH C4,
1.7 μm, 2.1 × 50 mm column (Waters, Spain). The mobile phase
consisted of (A) 10mMammonium formate and (B)methanol. A binary
step gradient at a flow rate of 0.400ml/minwas employed. Up to 4min,
the ratio of A and B was kept at 50:50 (v/v) and from 4 min to 8.5 min
the ratio was switched to 0:100 (v/v), before returning to the starting
conditions [A:B, 50:50 (v/v)] up to 8.6 min [15]. Source and desolvation
temperatures were set at 140 and 500 °C, respectively. Nitrogen was
used as both cone gas (150 l/h) and desolvation gas (800 l/h), and
argon was used as collision gas (0.14 ml/min). For detection and quan-
tification of rapamycin, we chose the ammonium ion, which give a peak
at give peak at m/z 931.6509, and the ammonium ion adducts corre-
sponding to m/z 864.4501 and 83.4604. The standard curve of
rapamycin was made at 25, 50, 100 and 200 ng/ml. The results were
expressed in ng rapamycin/ml of blood.
2.10. Statistical analysis
Number of animals in each group were calculated in order to detect
gross ~60% changes in the biomarkers measurements (based upon
alpha = 0.05 and power of beta = 0.8). We used the application avail-
able in: http://www.biomath.info/power/index.htm. Animals were ge-
notyped and randomly assigned in experimental groups in separate
cages by the technician of the animal facility. Data are expressed as
the mean ± SD of 5–10 experiments per group, except in the survival
analysis and rotarod test, where a higher number of animals were
used [12–37]. A one-way ANOVA with a Tukey's post hoc test was
used to compare the differences between three experimental groups.
Studies with two experimental groups were evaluated using unpaired
Student's t-test. A P-value of b.05 was considered to be statistically
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the Gehan-Breslow-Wilcoxon tests.2.11. Metabolomics analysis
The analysis of metabolites in extracts from brain and liver was
performed according to the Agilent METLIN/PCDL method using a
1290 infinity UHPLC coupled to a 6550 ESI-QTOF, as previously
described [36].2.12. Data availability
RNA-seq data have been deposited in the ArrayExpress database at
EMBL-EBI (www.ebi.ac.uk/arrayexpress) under accession number
E-MTAB-7794Fig. 1. Phenotypic characterization and survival of Coq9R239X mice after rapamycin treatment
Coq9R239X mice after 28 or 225 ppm rapamycin treatments [(a): Coq9+/+, n = 10; Coq9R239X
rapamycin treatment, n = 10. (b): Coq9+/+, n = 10; Coq9R239X, n = 10; Coq9R239X after 28 pp
(c) Rotarod test on Coq9+/+ mice (n = 49), Coq9R239X mice (n = 37), and Coq9R239X mice af
Coq9R239X mice and Coq9R239X mice after 225 ppm rapamycin treatment at 3 months of age.
225 ppm rapamycin treatments. The treatments started at 1 month of age. Coq9+/+, n = 1
Coq9R239X mice after 225 ppm rapamycin treatment, n = 15. Analysis using the log-rank (Ma
Coq9+/+ mice and Coq9R239X mice (P b 0.0001 and P b 0.0001, respectively); Coq9+/+ m
respectively); Coq9+/+ mice and Coq9R239X mice treated with rapamycin 225 ppm (P b 0
rapamycin 225 ppm (P b 0.0001 and P b 0.0001, respectively); and Coq9R239X mice treated w
and P = .0090, respectively). Data information: Data are expressed as mean ± SD. ⁎P b 0.0
rapamycin treatments. +++P b 0.001; Coq9R239X versus Coq9R239X after 28 or 225 ppm rapam
rapamycin treatment (one-way ANOVA with a Tukey's post hoc test or t-test).3. Results
3.1. Rapamycin does not modify the phenotypic features of Coq9R239X mice
To test whether rapamycin may have general therapeutic effects in
mitochondrial encephalomyopathies, we treated Coq9R239X mice with
two different concentrations of active encapsulated rapamycin added
into the chow. The two concentrations were 28 ppm (low dose),
which has been used in aging studies [2]; and 225 ppm (high dose),
which is similar to the dose used in the Ndufs4−/− mouse model [16].
The treatments started at the first month of age, previous to the emer-
gence of the severe disease symptoms. Coq9R239X showed a reduced
size and body weight, compared to the Coq9+/+ mice, in both males
(Fig. 1a) and females (Fig. 1b). These differences were already present
at the first month of age and became more evident over the time. Low
dose of rapamycin did not induce any change on the body weight in
males and females of Coq9R239X mice compared to untreated Coq9R239X
mice, while high-dose of rapamycin induced a dramatic decrease ins. (a, b) Body weight of males (a) and females (b) of Coq9+/+ mice, Coq9R239X mice, and
, n = 10; Coq9R239X after 28 ppm rapamycin treatment, n = 4; Coq9R239X after 225 ppm
m rapamycin treatment, n = 5; Coq9R239X after 225 ppm rapamycin treatment, n = 10].
ter 28 (n = 12) or 225 (n = 22) ppm rapamycin treatments. (d) Comparative image of
(e) Survival curve of the Coq9+/+ mice, Coq9R239X mice, and Coq9R239X mice after 28 or
0, Coq9R239X, n = 17, Coq9R239X mice after 28 ppm rapamycin treatment, n = 12, and
ntel-Cox) and the Gehan–Breslow–Wilcoxon tests shows significant differences between
ice and Coq9R239X mice treated with rapamycin 28 ppm (P b 0.0001 and P b 0.0001,
.0001 and P b 0.0001, respectively); Coq9R239X mice and Coq9R239X mice treated with
ith rapamycin 28 ppm and Coq9R239X mice treated with rapamycin 225 ppm (P = .0032
5; ⁎⁎P b 0.01; ⁎⁎⁎P b 0.001; Coq9+/+ versus Coq9R239X or Coq9R239X after 28 or 225 ppm
ycin treatments. ###P b 0.001; Coq9R239X after 28 ppm versus Coq9R239X after 225 ppm
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motor coordination, tested by rotarod assay. Rapamycin, at either low
or high dose, was not able to increase the latency to fall of Coq9R239X
mice on the rotarod assay (Fig. 1c). Consistent with these data,
rapamycin therapy did not extend the survival of Coq9R239X mice.
Even, the lifespan was significantly shortened at the higher dose of
rapamycin, for which most of the animal died between 3 and
4 months of age and all the mice were dead before 6 months of age
(Fig. 1e).
3.2. Brain injuries are still observed in Coq9R239X mice treated with
rapamycin
The lack of phenotypic improvement after rapamycin therapy
should be also observed at histopathologic level, sincewe previously re-
ported that Coq9R239X mice show severe spongiosis and reactive
astrogliosis in different brain areas, such as the pons, the medulla
oblongata and the diencephalon. Thus, we observed a profound
vacuolization and proliferation of astrocytes (as indicates the astrocytes'
marker GFAP) on the diencephalon and the pons of Coq9R239X mice
(Fig. 2, b1–b4; Fig. S1; Fig. S2, b1–b4; Fig. S3), compared to Coq9+/+
mice (Fig. 2, a1–a4; Fig. S1; Fig. S2 a1–a4; Fig. S3). These histopathologic
changes were also apparent in the treated Coq9R239X mice, although the
astrogliosis was partially reduced, especially in the diencephalon (Fig. 2,
c1–c4, d1–d4; Fig. S1; Fig. S2, c1–c4, d1–d4; Fig. S3). Because rapamycin
has potent immunosuppressive properties and it induced a reduction of
microgliosis in the Ndufs4−/− mice [1], we also tried to detect the mi-
croglia in the cerebral preparations. However, microgliosis was notFig. 2. Pathological features in brain tissue sections of Coq9R239X after 28 or 225 ppm rapamycin
mice (a1 and a2), Coq9R239Xmice (b1 and b2), Coq9R239Xmice after 28 ppm rapamycin treatment
d3-d4) Anti-GFAP stain in the diencephalon of Coq9+/+mice (a3 and a4), Coq9R239Xmice (b3 and
225 ppm rapamycin treatment (d3 and d4). (a5-a6 to d5-d6) Anti-Iba-1 stain in the diencephal
rapamycin treatment (c5 and c6), and Coq9R239X mice after 225 ppm rapamycin treatment (d
mice (e1 and e2), Coq9R239X mice (f1 and f2), and Coq9R239X mice after 28 (g1 and g2) or 225 pp
(a3–d3); 200 μm (a4–d4); 500 μm (a5–d5); 200 μm (a6–d6). The yellow arrows indicated the argenerally observed in the diencephalon and the pons of Coq9R239X
mice (Fig. 2, b5–b6; Fig. S1; Fig. S2, b5–b6) and only some small spots,
very focused and infrequent, of microglia proliferation were observed
in some preparations. The Iba-1 images of these cerebral areas in the
mutant mice under rapamycin treatment, either at low (Fig. 2, c5–c6;
Fig. S1; Fig. S2, c5–c6) or high doses (Fig. 2, d5–d6; Fig. S1; Fig. S2, d5–
d6), were comparable to those on Coq9+/+ (Fig. 2, a5–a6; Fig. S1, a5–
a6) and Coq9R239X mice (Fig. 2, b5–b6; Fig. S1; Fig. S2, b5-b6).
The pathological manifestations in the brain of Coq9R239X mice
were further corroborated by magnetic resonance imaging, in which
Coq9R239Xmice showed abundant lesions (Fig. 2, f1–f2) thatwere persis-
tent in the brain of the treated mice at either low or high doses of
rapamycin (Fig. 2, g1–h2). Therefore, rapamycin treatment did not cor-
rect the main pathological features on the brain of Coq9R239X mice and,
consequently, it did not improve the phenotype and it did not increase
the lifespan on this mouse model.
3.3. Rapamycin inhibits mTORC1 but it does not induce autophagy in Coq9-
R239X mice
The levels of rapamycin in the blood increased during its oral admin-
istration (Table 1), and its levels inmutantmice treatedwith rapamycin
at 225 ppmwere comparable to those published elsewhere [16]. To de-
termine if the supplementation of rapamycin in the chowwas able to in-
hibit mTORC1 in the Coq9R239X mice, we analyzed the phosphorylation
state of S6R protein (p-S6R), one of the targets ofmTORC1, in heart, kid-
ney, liver and brain. The p-S6R/S6R ratio was similar in the four tissues
of Coq9+/+ and Coq9R239X mice (Fig. 3a–d), although the tissues oftreatments. (a1–a2 to d1–d2) Hematoxylin and eosin stain in the diencephalon of Coq9+/+
(c1 and c2), and Coq9R239Xmice after 225 ppm rapamycin treatment (d1 and d2). (a3-a4 to
b4), Coq9R239Xmice after 28 ppm rapamycin treatment (c3 and c4), and Coq9R239Xmice after
on of Coq9+/+ mice (a5 and a6), Coq9R239X mice (b5 and b6), Coq9R239X mice after 28 ppm
5 and d6). (e1–e2 to h1-h2) Magnetic Resonance Images of the diencephalon of Coq9+/+
m rapamycin treatment (h1 and h2). Scale bars: 500 μm (a1–d1); 200 μm (a2–d2); 500 μm
eas of increased T2 signal, which is characteristic of lesions in specific brain areas.
Table 1
Levels of rapamycin in blood.
Genotype Administration route Number of samples with detected levels of rapamycin Type of samples Levels of rapamycin (ng/ml)
Coq9+/+ not treated 0/5 Blood UND
Coq9R239X not treated 0/5 Blood UND
Coq9R239X Oral (chow at 225 ppm) 9/9 Blood 605.3 ± 436.2
Rapamaycin therapy started in animals at 1 month of age and the blood samples were collected in animals at three moths of age.
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dose, rapamycin did not significantly modify the p-S6R/S6R ratio in
any of the four tissues (Fig. 3a–d). At the higher dose, however, all the
examined tissues responded to rapamycin inhibition, as they experi-
enced a reduction in the p-S6R/S6R ratio, compared to Coq9+/+ and
Coq9R239X mice (Fig. 3a–d).
One of themTORC1 downstream target process is autophagy. Partic-
ularly, several studies have shown that the inhibition of mTORC1 in-
duces the mechanisms to promote autophagy in mammalian cells
[17]. Thus, we have analyzed two different markers of autophagy, the
LC3II/LC3I ratio and the levels of p62, in our experimental conditions.
In the heart and the brain, we did not detect any difference of these au-
tophagymarkers between the four experimental groups (Fig. 3e and h).
In the kidneys, the levels of p62were decreased in the three experimen-
tal groups of Coq9R239X mice, while the LC3II/I ratio was only increased
in Coq9R239Xmice treatedwith the high dose of rapamycin (Fig. 3f), sug-
gesting that this therapeutic condition may exacerbate the autophagic
process. In the liver, we only observed an increase of the LC3II/I ratio
in Coq9R239X mice treated with the high dose of rapamycin, compared
to Coq9+/+ mice (Fig. 3g). Therefore, contrary to what it was expected,
therewas no evidence of general autophagy induction in Coq9R239Xmice
after 2 months of rapamycin treatment, a fact that may be attributed to
an early autophagy response induced by CoQ deficiency, as it has been
previously reported in vitro [18] and it is also suggested in our analysis
in the brain at 2 months of age (Fig. S4).
3.4. Rapamycin modifies the transcriptomics and metabolomics profiles in
Coq9R239X mice
Although the low dose of rapamycin does not induce a widespread
inhibition ofmTORC1, its systemic effects can encourage profoundalter-
ations in different cellular and tissue pathways, as it has previously re-
ported [19]. To check this possibility, we performed a transcriptomics
and metabolomics analyses in the brain of Coq9R239X mice treated with
the low dose of rapamycin. To better understand the changes induced
by rapamycin, those analyses were extended to a transcriptomics anal-
ysis in the brain of Coq9R239X mice treated with the high dose of
rapamycin; and to a metabolomics analysis in the liver of Coq9R239X
mice treated with the low dose of rapamycin since this tissue is a pri-
mary target of the circulating rapamycin [19].
Our transcriptomics analysis revealed 138 differentially expressed
genes (DEGs) between Coq9R239X and Coq9+/+ mice (82 up-regulated
and 56 down-regulated) (Supplementary File 1); 2876 DEGs between
Coq9R239X mice and Coq9R239X mice treated with the low dose of
rapamycin (166 up-regulated and 2710 down-regulated) (Supplemen-
tary File 1); and 3007 DEGs between Coq9R239Xmice and Coq9R239Xmice
treated with the high dose of rapamycin (2919 up-regulated and 88
down-regulated) (Supplementary File 1) (adjusted P value b 0.05).
The data analysis with the Ingenuity Pathway Analysis (IPA) software
gave us the identification of altered pathways and networks (Fig. 4).
Among others, we observed an alteration in pathways related with in-
flammation (e.g. IL-8, MAPK, IL-2, NF-κB or immune cells receptors) in
the midbrain of Coq9R239X mice compared to Coq9+/+ mice (Fig. 4a).
Most of these pathways were still altered after the treatment with
rapamycin, both at low and high doses (Fig. 4b and c). Nevertheless,
we observed that rapamycin treatment altered some pathways related
to mitochondrial biology, such as, mTOR signaling, sirtuin signalingpathway, AMPK signaling, NRF-2 mediated oxidative stress response,
PPARα/RXRα signaling or mitochondrial dysfunction (Fig. 4b and c;
Fig. S5), all of them potential therapeutic targets in mitochondrial dis-
eases [20–23].
The alterations in gene expression were reflected in changes in the
metabolic profile in the experimental groups. The main pathways af-
fected by the mutation and/or by the treatment with low dose of
rapamycin were related to lipid metabolism, nucleotides metabolism,
amino acid metabolism, vitamins, oxidative stress, carbohydrates me-
tabolism and corticosterone (Fig. 5). Those changes were more pro-
nounced in the liver (Fig. 5b) than in the brain (Fig. 5a); and
especially relevant were the effects of low dose of rapamycin on the nu-
cleotides metabolism and the lipid metabolism in liver (Fig. 5b).
3.5. Rapamycin treatment does not interfere in the mitochondrial bioener-
getics of Coq9R239X mice
To checkwhether the transcriptomics andmetabolomics alterations
could influence the mitochondrial bioenergetics, we first measured the
mitochondrial respiration in the kidneys and the brain, two of the prev-
alent affected tissues in primary CoQ deficiency. Both tissues of
Coq9R239X mice showed an impaired mitochondrial respiration, with
lower phosphorylating respiratory state (state 3o) compared to the
same tissues in Coq9+/+ mice (Fig. 6a and f). After 2 months of
rapamycin treatment, at either low or high dose, the mitochondrial res-
piration in the kidneys and the brain of Coq9R239X mice was also lower
than in the same tissues in Coq9+/+ mice (Fig. 6a and f). In agreement
with that, the activities of the mitochondrial CI + CIII and CII + CIII
were decreased in the kidneys and the brain of Coq9R239X mice, and
the rapamycin treatment did not induce any change on these parame-
ters (Fig. 6b, c, g and h). The reduction on the OXPHOS capacity induces
the anaerobic metabolism, as it is reflected in the detection of lactate in
the spectroscopy of the brain of Coq9R239X mice (Fig. 5i). The rapamycin
treatment did not normalize the energy metabolism and accumulation
of lactate was also detected in the mutant animals treated with
rapamycin (Fig. 6i). Together, these data may indicate that rapamycin
did no act in OXPHOS capacity, including the levels of CoQ, which
were reduced in the three experimental groups of Coq9R239X mice com-
pared to Coq9+/+ mice (Fig. 6d, e, j and k). Consistent with that, the ac-
cumulation of DMQ, the substrate of the hydroxylase COQ7, persisted in
the Coq9R239X mice treated with either low or high dose of rapamycin
(Fig. S6).
3.6. Modulation of mTORC1 downstream pathways did not provide thera-
peutic benefits in Coq9R239X mice
Because the inhibition of mTORC1 produce pleiotropic results and
induce side effects that can mask its therapeutic potential, we also
tested the treatment with two molecules that can modulate specific
mTORC1 downstreampathways, i.e.: trehalose, that can induce autoph-
agy in an mTOR-independent manner and it has been considered as a
neuroprotector in some neurodegenerative diseases [5]; and PF-
4708671, that inhibits the protein and lipid synthesis by the specific in-
hibition of the S6K1protein [6]. The treatmentwith trehalose did not in-
duce anymorphological improvement in the pons of the Coq9R239Xmice
(Fig. S7, a5–a6, b5–b6), since the spongiosis and astrogliosis were simi-
lar to those in the untreated mutant animals (Fig. S7, a3–a4, b3–b4).
Fig. 3. mTORC1 inhibition and autophagy alterations in Coq9R239X tissues after rapamycin treatments. (a–d) Representative western blots of the phosphorylation state of the mTORC1
target S6R protein in heart (a), kidney (b), liver (c), and brain (d). (e–h) Representative images of western blots of p62 and LC3 autophagy markers in heart (e), kidney (f), liver (g),
and brain (h). Coq9+/+, n = 4–8; Coq9R239X, n = 5–10; Coq9R239X mice after 28 ppm rapamycin treatment, n = 5; and Coq9R239X mice after 225 ppm rapamycin treatment, n = 5. Data
are expressed as mean ± SD. ⁎P b 0.05; ⁎⁎P b 0.01; Coq9+/+ versus Coq9R239X or Coq9R239X after 28 or 225 ppm rapamycin treatment. +P b 0.05; +++P b 0.001; Coq9R239X versus
Coq9R239X after 28 or 225 ppm rapamycin treatment; ##P b 0.01; Coq9R239X after 28 ppm versus Coq9R239X after 225 ppm rapamycin treatment (one-way ANOVA with a Tukey's post
hoc test or t-test).
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Fig. 4. RNA-Seq analysis using the IPA software. Effect of rapamycin on the biological pathways inmidbrain ofCoq9R239Xmice. Only pathwayswith –log (P-value) ≥ 2with amaximumof 70
of the most significant pathways are considered for representation. Comparison of Coq9+/+ and Coq9R239X mice (a), and Coq9R239X mice and Coq9R239X mice after 28 (b) or 225 (c) ppm
rapamycin treatments biological processes. Coq9+/+, n = 7; Coq9R239X, n = 8; Coq9R239X mice after 28 ppm rapamycin treatment, n = 5; and Coq9R239X mice after 225 ppm rapamycin
treatment, n = 4.
518 E. Barriocanal-Casado et al. / EBioMedicine 42 (2019) 511–523Those featureswere absent in thewild-type animals (Fig. S7, a1–a2, b1–
b2). The CoQ-dependent mitochondrial complexes activities, CI + III
and CII + CIII, were reduced in Coq9R239X mice and Coq9R239X mice
treated with trehalose, compared to Coq9+/+ mice, in both kidneys
(Fig. S7c and e) and brain (Fig. S7d and f). Also, the spongiosis and
astrogliosis persisted in the pons of the Coq9R239Xmice during the treat-
mentwith PF-4708671 (Fig. S7, g5–g6, h5–h6), as it was clearly observ-
able after comparing the images to those of the untreated Coq9R239X
mice (Fig. S7, g3–g4, h3–h4), and Coq9+/+ mice (Fig. S7, g1–g2, h1–
h2). The immunohistochemistry for the detection of microglia did not
detect significant and reliable differences between the three experi-
mental groups (Fig. S7, i1–i6). Consistent with these results, the mito-
chondrial respiration was decreased in Coq9R239X mice and Coq9R239X
mice treated with PF-4708671, compared to Coq9+/+ mice, in both kid-
neys (Fig. S7j and k) and brain (Fig. S7l and m). Because the two treat-
ments did not show any improvement in the histopathological
features and the bioenergetic status of the Coq9R239X mice (Fig. S7),
both treatments failed to increase the survival of the mutant animals
(data not shown).
4. Discussion
It has been reported that the inhibition ofmTORC1 by rapamycin ad-
ministration has therapeutic effects, at different intensities, in a variety
of preclinical models of mitochondrial diseases with diverse molecular
defects and phenotypes. However, our study fails to demonstrate that
the inhibition of mTORC1 induces any therapeutic outcomes in a
mouse model of mitochondrial encephalopathy due to CoQ deficiency.
Therefore, contrary to what it could be speculated from the previous
studies, this work points out that chronic rapamycin treatment is not
a valid therapy for all cases of mitochondrial diseases, not even for allcases ofmitochondrial encephalopathieswhere the central nervous sys-
tem is the most affected structure.
In 2013, Johnson and colleagues showed that intraperitoneal (i.p.)
administration of high doses of rapamycin dramatically reduced the
gliosis and the histopathological signs on a mouse model of Leigh syn-
drome due to mitochondrial complex I deficiency (Ndufs4−/− model),
thus increasing the survival [1]. This effect of i.p. administration of
high doses of rapamycin was independently corroborated [24], and
two other studies reported that oral administration of different
doses of rapamycin, starting from 42 ppm of dietary administration,
delayed the development of neurological symptoms and extended
the lifespan in Ndufs4−/− mice, confirming also that the route of ad-
ministration is not a limitation [16,25]. However, in the four studies
the underlying mitochondrial dysfunction was not mitigated, and the
mechanism by which rapamycin produced the therapeutic outcomes
was not sufficiently elucidated. Nevertheless, theses studies opened a
new perspective for testing rapamycin therapy in other cases of mito-
chondrial diseases. Thus, in other mouse model of mtDNA depletion
and encephalopathy due to thymidine kinase 2 (TK2) deficiency (the
Tk2H126N model), low doses of oral rapamycin induced a very mild in-
crease in lifespan without any improvement in the morphological fea-
tures [19]; and in two mouse models with milder phenotypes, the
rapamycin administration also resulted in therapeutic benefits, i.e.:
(1) in the mouse model of mitochondrial myopathy with COX defi-
ciency due to the muscle-specific ablation of the Cox15 gene (the
Cox15sm/sm model), the i.p. administration of high doses of rapamycin
improved the locomotor activity, corrected the histopathological fea-
tures and increased the COX activity in muscle [26]; and (2) in the
mouse model of late-onset mitochondrial myopathy due to a defect
in the helicase Twinkle (the Twnkdup model), the i.p. administration
of high doses of rapamycin downregulated the components of the
Fig. 5.Metabolomics analysis. Analysis of brain (a) and liver (b) metabolites of Coq9+/+ (black bars), Coq9R239X (blue bars), and Coq9R239X after 28 ppm rapamycin treatment (red bars)
mice (n = 4 for each group). Data are expressed as mean ± SD. ⁎P b 0.05; ⁎⁎P b 0.01; ⁎⁎⁎P b 0.001; Coq9+/+ versus Coq9R239X or Coq9R239X after 28 ppm rapamycin treatment. +P b
0.05; ++P b 0.01; Coq9R239X versus Coq9R239X after 28 ppm rapamycin treatment (one-way ANOVA with a Tukey's post hoc test or t-test).
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521E. Barriocanal-Casado et al. / EBioMedicine 42 (2019) 511–523integrated mitochondrial stress response, thus reversing the myopa-
thy progression [27]. Contrary to these results, the oral administration
of rapamycin, either at low (28 ppm) or high dose (225 ppm), did not
produce any therapeutic benefits in Coq9R239X mice. Even, the group of
animals with the high dose of rapamycin experienced an aggravation
on the brain lesions, resulting in a mild decrease in the survival, which
could be attributed to the reported side effects of this drug, e.g. throm-
bocytopenia and hyperlipidemia, impaired wound healing, nephrotox-
icity, and altered insulin sensitivity [28]. In this regard, it is important
to note that inhibition of mTORC1 was only clearly detected at the
high dose, although the low dose induced a very mild inhibition
only in heart and liver. This is consistent with the fact that rapamycin
is able to induce morphological and phenotypic improvements with
survival increase in Ndufs4−/− mice in a dose-dependent manner
[1,16,25]. In fact, our transcriptomics analysis in midbrain revealed
dose-dependent differences in the DEGs, which may account systemic
effects of the rapamycin administration and specific effects related to
the inhibition of mTORC1 in the midbrain.
The differences in the therapeutic effects of rapamycin administra-
tion in diverse mouse models of mitochondrial diseases must be
explained by the specific therapeutic mechanisms induced by
rapamycin. First, in the symptomatic tissues of Ndufs4−/− and Twnkdup
mice, the p-S6/S6 ratio, used as a marker of the mTORC1 activity, was
significantly increased compared to age match wild-type animals,
while rapamycin treatment reduced this p-S6/S6 ratio [1,27]. In the
Coq9R239X mice, we observed the same effect of rapamycin at the high
dose but the brain of both untreated mutant mice and wild-type mice
have similar p-S6/S6 ratio. Similarly, an overactivation of mTORC1 was
not observed in Tk2H126N and Cox15sm/smmice, although in thosemodels
rapamycin was therapeutically relevant [19,26]. Because of the inhibi-
tion of mTORC1, rapamycin was able to lessen the microgliosis and
downregulate microglia-related inflammatory genes in Ndufs4−/−
mice [1,24]. This effect could not be induced in Coq9R239X mice because
we were not able to detect any consistent sign of microgliosis in this
mouse model. Moreover, the differentially-expressed inflammatory
genes observed in the transcriptomics analysis were related to the pro-
liferation of astrocytes and not to the proliferation of microglia [9] and
some of the key inflammatory genes downregulated by rapamycin in
Ndufs4−/− mice (Tlr2, Cxcl10, Ccl5 and Aif1) were not picked up in our
transcriptomics analysis [24]. Another therapeutic mechanism attrib-
uted to rapamycin inmitochondrial diseases is the activation of autoph-
agy and the lysosomal biogenesis [17,26]. Our transcriptomics analysis
did not show any clue of lysosomal biogenesis induction and the levels
of autophagy markers did not suggest a general rapamycin-mediated
autophagy induction. The lack of a strong autophagic activity may be
due to that fact that CoQ deficiency induces an early autophagy re-
sponse, as it is suggested in the brain of Coq9R239X at 2 months of age,
and as it has been reported in vitro [18]. This early event may be
disrupted over the time by an impairment of lysosomes induced by
the oxidative damage [29]. In fact, CoQ deficiency induces oxidative
stress in vitro and in vivo [30–32], and the pons and diencephalon of
Coq9R239X mice show increased signals of markers of oxidative damage
[4,9,11]. A third rapamycin-mediated therapeutic mechanism is the in-
hibition of the integratedmitochondrial stress response, which includesFig. 6.Mitochondrial bioenergetics is not affected after rapamycin treatments. (a,f) Oxygen con
ADP and substratesmeasured bymitochondrial respiration in kidney (a) and brain (f). (a) Coq9+
Coq9R239X mice after 225 ppm rapamycin treatment, n = 4. (f): Coq9+/+, n = 3; Coq9R239X, n
225 ppm rapamycin treatment, n = 4. (b,g) CoQ-dependent Complex I + III activity in kidney
rapamycin treatment, n = 4; and Coq9R239X mice after 225 ppm rapamycin treatment, n = 4.
n = 5; and Coq9R239X mice after 225 ppm rapamycin treatment, n = 4. (c, h) CoQ-dependent
12; Coq9R239X mice after 28 ppm rapamycin treatment, n = 4; and Coq9R239X mice after 225 p
after 28 ppm rapamycin treatment, n = 5; and Coq9R239X mice after 225 ppm rapamycin trea
brain (j and k, respectively). (d, j) Coq9+/+, n = 9; Coq9R239X, n = 9; Coq9R239X mice afte
treatment, n = 5. (e, k) Coq9+/+, n = 8; Coq9R239X, n = 9; Coq9R239X mice after 28 ppm rapa
(i) Lactate peak in the brain of Coq9+/+ mice, Coq9R239X mice and Coq9R239X mice after 28 pp
Coq9R239X or Coq9R239X after 28 or 225 ppm rapamycin treatment (one-way ANOVA with a Tukthe repression of the mitochondrial unfolded protein response
(UPRmt). However, the deleterious effect of the induction of UPRmt
has been only identified in themodel Twnkdup of mitochondrial myopa-
thy [27,33], and the levels of two proteins involved in UPRmt, the
mitochondrial proteins stress-70 protein (HSPA9 or GRP75) and
ATP-dependent Clp protease proteolytic subunit (CLPP), are unaltered
in other mouse model of CoQ deficiency due to a different mutation
in the Coq9 gene [34]. The last rapamycin-mediated therapeutic
mechanism is the partial bypass of the OXPHOS defect by tapping into
alternative energy reserves, such as amino acids and lipids [19]. This
mechanism could be therapeutically relevant in cases of deficiencies in
mitochondrial Complex I or Complex II. Nevertheless, this effect may
have some limitations under CoQ deficiency because different pathways
of the energy metabolism, e.g. carbohydrate metabolism, lipid metabo-
lism, sulfide metabolism and pyrimidine metabolism, converge in the
CoQ-junction to enter electrons into the mitochondrial respiratory
chain [35,36].Moreover, we observed some changes in the levels ofme-
tabolites related to amino acid, carbohydrate, nucleotides and lipid me-
tabolism in liver, with a limited effect on the brain, as it was reported in
the Tk2H126N model [19]; but the changes in lipid metabolism were re-
lated to eicosanoid metabolism, rather than to β-oxidation and energy
metabolism.
While our results suggest that rapamycin administration is not a
therapeutic option in primary CoQ deficiency, a recent study in the
mouse model of CoQ deficiency due to a point mutation in the CoQ
biosynthetic gene Pdss2 (the Pdss2kd/kd model) showed that oral
administration of high doses of rapamycin (225 ppm) reduced the albu-
minuria in this mousemodel of nephrotic syndrome [37]. However, the
survival was not analyzed and the morphological structure of the renal
glomeruli was not shown [37]. Thus, the reduction in the levels of the al-
bumin in the urine could merely reflect the reduction in the phosphor-
ylation of 4E-BP1 and S6K1 because of the inhibition of mTORC1 and,
consequently, a perturbation of the protein synthesis [17]. Also, we
need to take into account that the different response to rapamycin ad-
ministration may be due to two important dissimilarities between the
Pdss2kd/kd and Coq9R239Xmodels: 1) Pdss2kd/kdmice have severe CoQ de-
ficiency while Coq9R239X mice have severe CoQ deficiency together with
an accumulation of the toxic intermediate demethoxyubiquinone
(DMQ) [9], which is still accumulated under rapamycin treatment and
produces a non-functional competition with CoQ [9,38,39]; and
2) while Pdss2kd/kd mice develop nephrotic syndrome and die between
5 and 11 months age [23], Coq9R239X mice develop a mitochondrial en-
cephalopathy, with a potential contribution of endocrine interactions
in the pathological features of the diseases [9], and die between 3 and
7 months age [4,9].
In conclusion, our study suggests that the use of rapamycin in
patients with mitochondrial diseases must be evaluated for each
particular case. The fail of therapeutic benefits in the Coq9R239X
mouse model may be due to different factors, such as: 1) the lack
of microgliosis-derived neuroinflammation in this model of en-
cephalopathy; 2) the lysosomes impairment, which avoid the in-
duction of an autophagy flux; or 3) the need of some residual
function of the CoQ-junction in order to promote the supply of
electron into the mitochondrial respiratory chain from differentsumption rate (top) and ADP-stimulated respiration (State 3o, bottom) in the presence of
/+, n=3; Coq9R239X, n=3; Coq9R239Xmice after 28 ppm rapamycin treatment, n=3; and
= 3; Coq9R239X mice after 28 ppm rapamycin treatment, n = 4; and Coq9R239X mice after
(b) and brain (g). (b) Coq9+/+, n = 12; Coq9R239X, n = 11; Coq9R239X mice after 28 ppm
(g) Coq9+/+, n = 8; Coq9R239X, n = 9; Coq9R239X mice after 28 ppm rapamycin treatment,
Complex II + III activity in kidney (c) and brain (h). (c) Coq9+/+, n = 13; Coq9R239X, n =
pm rapamycin treatment, n = 4. (h) Coq9+/+, n = 9; Coq9R239X, n = 9; Coq9R239X mice
tment, n = 4. (d, e, j, k) Levels of CoQ9 and CoQ10 in kidney (d and e, respectively) and
r 28 ppm rapamycin treatment, n = 5; and Coq9R239X mice after 225 ppm rapamycin
mycin treatment, n = 6; and Coq9R239X mice after 225 ppm rapamycin treatment, n = 5
m. Data are expressed as mean ± SD. ⁎P b 0.05; ⁎⁎P b 0.01; ⁎⁎⁎P b 0.001; Coq9+/+ versus
ey's post hoc test or t-test).
522 E. Barriocanal-Casado et al. / EBioMedicine 42 (2019) 511–523metabolic sources. Therefore, the translation of this therapy into
the clinic requires additional studies and the consideration of the
particularities of each mitochondrial disease. Moreover, the devel-
opment of rational therapies must provide better therapeutic out-
comes with minimum side-effects, as it has been demonstrated,
at preclinical level, with the dNTPs/nucleosides therapy in Tk2 de-
ficiency [40,41], with AICAR administration or OPA1 overexpres-
sion in COX deficiency [20,42], or with the β-resorcylic acid
therapy in cases of CoQ deficiency due to defects in the CoQ bio-
synthetic genes Coq7 or Coq9 [9,43].
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